文献速递基础与转化研究新药、器械与细胞基因治疗研发

基因修饰慢病毒保护微血管功能减轻正常组织晚期放疗损伤

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.
PubMed 文献 · Sci Transl Med · 2018-01-01

研究在游离皮瓣晚期放疗损伤动物模型中,经动脉注射慢病毒载体过表达SOD2或敲低CTGF,单药分别维持皮瓣体积或减少皮肤挛缩,联合治疗同时改善两者并减少纤维化,且SOD2过表达未削弱放疗对肿瘤的疗效。

要点

  • LVSOD2单药放疗前给药维持皮瓣体积,LVshCTGF单药减少皮肤挛缩。
  • 联合治疗同时改善体积丢失和皮肤挛缩,并减少放疗后纤维化负担。
  • SOD2过表达在肿瘤复发模型中未削弱放疗疗效,似有增强作用。

核心结论

  • 靶向血管内递送LVSOD2与LVshCTGF联合治疗可减轻正常组织晚期放疗损伤严重程度,且不削弱放疗抗肿瘤疗效,值得转化评估。

研究设计与样本

  • 在游离皮瓣晚期放疗损伤动物模型中,经动脉注射慢病毒载体过表达SOD2或shRNA敲低CTGF,靶向血管 compartment。

主要发现

  • 放疗前LVSOD2单药维持皮瓣体积,LVshCTGF单药减少皮肤挛缩。
  • 联合治疗组皮瓣体积丢失和皮肤挛缩均改善,两种治疗均减少放疗后纤维化负担。
  • 晚期放疗损伤与血管灌注受损、内皮通透性丧失和间质缺氧相关,治疗模型中均逆转。
  • 肿瘤复发模型中,正常组织SOD2过表达未削弱放疗对肿瘤细胞的疗效,似有增强。

临床怎么用

  • 游离皮瓣靶向基因治疗可能作为减轻乳房切除术后即刻重建皮瓣晚期放疗损伤的转化方向。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy (RT) are characterized by vascular dysfunction and fibrosis causing volume loss and tissue contracture, for example, in the free flaps used for immediate breast reconstruction after mastectomy. We evaluated the efficacy of lentivirally delivered superoxide dismutase 2 (SOD2) overexpression and connective tissue growth factor (CTGF) knockdown by short hairpin RNA in reducing the severity of LAEs in an animal model of free flap LAEs. Vectors were delivered by intra-arterial injection, ex vivo, to target the vascular compartment. LVSOD2 and LVshCTGF monotherapy before irradiation resulted in preservation of flap volume or reduction in skin contracture, respectively. Flaps transduced with combination therapy experienced improvements in both volume loss and skin contracture. Both therapies reduced the fibrotic burden after irradiation. LAEs were associated with impaired vascular perfusion, loss of endothelial permeability, and stromal hypoxia, which were all reversed in the treatment model. Using a tumor recurrence model, we showed that SOD2 overexpression in normal tissues did not compromise the efficacy of RT against tumor cells but appeared to enhance it. LVSOD2 and LVshCTGF combination therapy by targeted, intravascular delivery reduced LAE severities in normal tissues without compromising the efficacy of RT and warrants translational evaluation as a free flap-targeted gene therapy.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Khan AA, Paget JT, McLaughlin M, et al. Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Sci Transl Med. 2018. PMID: 29367346. doi:10.1126/scitranslmed.aar2041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。